Leucemia de células peludas en paciente geriátrico. Reporte de caso y revisión de la literatura

Abstract

process that evolves to B cells. It is a rare entity that manifests in the last decades of life with a peak incidence between 60 and 70 years. The etiology is currently uncertain however 90% of cases derive from a BRAF V600E mutation. The course of the disease is indolent, so the patient is usually asymptomatic; however, when the symptoms are present, symptoms B, pancytopenia and splenomegaly stand out.

The diagnosis is made through a correct history, blood count, bone marrow biopsy, flow cytometry and a CT scan that helps us identify the progression of the disease. Purine analogues such as Cladribine are the first-line treatment, achieving complete remission in 90% of cases. An important point to highlight is the difficult access in our country due to its cost and availability. monoclonal studies can be used together when the disease is refractory to conventional treatment. The objective of this report is to present the case of a patient with hairy cell leukemia, and demonstrate the importance of a quick and accurate diagnosis, to treat effectively and prevent this disease from becoming a growing health problem.

A clinical case of a 71-year-old male patient with weight loss, splenomegaly accompanied by leukopenia and thrombocytopenia is presented, receiving purine analogues as the first choice, reaching complete remission. The objective of this report is to present the case of a patient with hairy cell leukemia, and demonstrate the importance of a quick and accurate diagnosis, to treat effectively and prevent this disease from becoming a growing health problem